Skip to search formSkip to main contentSkip to account menu

camonagrel

Known as: 5-(2-imidazol-1-ylethoxy)-1-indancarboxylic acid 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Camonagrel is a novel selective thromboxane synthetase inhibitor. The aim of this study was to determine its main pharmacokinetic… 
2003
2003
The aim of this study was to compare the effects of a new thromboxane synthase inhibitor, camonagrel, on platelet aggregation and… 
2002
2002
Recent evidence suggests that hypoxic pulmonary vasoconstriction (HPV) is mediated by hypoxia-induced closure of voltage-gated… 
1999
1999
We characterised early circulatory and respiratory responses to lipopolysaccharide from E. coli (LPS, serotype 0127:B8) in the… 
1999
1999
The mechanism of early pulmonary and systemic haemodynamic response to intravenous infusion of LPS from Escherichia coli was… 
1998
1998
We present for the first time direct continuous assay of NO concentration (porphyrinic sensor) in the lung parenchyma of Sprague… 
1996
1996
Six hours after administration of E. Coli endotoxin (LPS) into rats (10 mg kg-1, i.p.) a significant (P < 0.001) decline in the… 
1996
1996
Here we report that streptokinase is responsible for forming thrombi both in vitro on blood-superfused endothelial cells of… 
1995
1995
So far pharmacological consequences of inhibition of thromboxane A2 (TXA2) synthase by imidazole derivatives (e.g., camonagrel or…